Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Enfuvirtide resistance mutations: impact on human immunodeficiency virus envelope function, entry inhibitor sensitivity, and virus neutralization.

Journal of virology - 1 Apr 2005

Reeves Jacqueline D, Lee Fang-Hua, Miamidian John L, Jabara Cassandra B, Juntilla Marisa M, Doms Robert W

Abstract excerpt

Enfuvirtide (ENF/T-20/Fuzeon), the first human immunodeficiency virus (HIV) entry inhibitor to be licensed, targets a structural intermediate of the entry process. ENF binds the HR1 domain in gp41 after Env has bound CD4, preventing conformational changes needed for membrane fusion. Mutations in HR1 that confer ENF resistance can arise following ENF therapy. ENF resistance mutations were introduced into an R5-...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CD8-Positive T-Lymphocytes
Share to Enfuvirtide

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Products, env

Share to HIV Envelope Protein gp41

Share to HIV Fusion Inhibitors

Share to Neutralization Tests

Share to Peptide Fragments

Source

Open in PubMed Open full text

Identifiers

PMID: 15795284
DOI: 10.1128/JVI.79.8.4991-4999.2005
PMCID: PMC1069568

Genes

CCR5
CXCR4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Enfuvirtide resistance mutations: impact on human immunodeficiency virus envelope function, entry inhibitor sensitivity, and virus neutralization.PMID 15795284Read ↗

Impact of mutations in the coreceptor binding site on human immunodeficiency virus type 1 fusion, infection, and entry inhibitor sensitivity.Semantic proximity Read ↗

HIV resistance to the fusion inhibitor enfuvirtide: mechanisms and clinical implications.Semantic proximity Read ↗

HR-2 Mutations in Human Immunodeficiency Virus Type 1 gp41 Restore Fusion Kinetics Delayed by HR-1 Mutations That Cause Clinical Resistance to EnfuvirtideSemantic proximity Read ↗

Resistance to enfuvirtide, the first HIV fusion inhibitor.Semantic proximity Read ↗

Clinical resistance to enfuvirtide does not affect susceptibility of human immunodeficiency virus type 1 to other classes of entry inhibitors.Semantic proximity Read ↗

Impact of the HIV-1 env genetic context outside HR1-HR2 on resistance to the fusion inhibitor enfuvirtide and viral infectivity in clinical isolates.Semantic proximity Read ↗

Detailed mechanistic insights into HIV-1 sensitivity to three generations of fusion inhibitors.Semantic proximity Read ↗

HIV entry inhibitors: mechanisms of action and resistance pathwaysSemantic proximity Read ↗

Resistance of human immunodeficiency virus type 1 to a third-generation fusion inhibitor requires multiple mutations in gp41 and is accompanied by a dramatic loss of gp41 function.Semantic proximity Read ↗

Massively parallel profiling of HIV-1 resistance to the fusion inhibitor enfuvirtideSemantic proximity Read ↗

Human immunodeficiency virus type 1 variants resistant to first- and second-version fusion inhibitors and cytopathic in ex vivo human lymphoid tissue.Semantic proximity Read ↗

Role of the envelope genetic context in the development of enfuvirtide resistance in human immunodeficiency virus type 1-infected patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.